HCM
VRTX icon

Hayman Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hayman Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$10.4M – 8
2015
Q3 		$10.4M Buy
100,000
+91,051
+1,017% +$11.7M 4.81% 7
2015
Q2 		$1.1M Buy
+8,949
New +$1.13M 0.13% 39

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hayman Capital Management's VRTX Position: Q4 2015 in Review

Hayman Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 100,000 shares — an estimated $10.4M sold.

Hayman Capital Management first reported a position in VRTX in Q2 2015 and held it in 2 quarters. The position peaked at $10.4M in Q3 2015. 518 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

  • Hayman Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Hayman Capital Management sold 100,000 Vertex Pharmaceuticals shares in Q4 2015, an estimated $10.4M.
  • Hayman Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Hayman Capital Management's Vertex Pharmaceuticals position peaked at $10.4M in Q3 2015.
  • 518 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Hayman Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.